Idecabtagene vicleucel vs KLN-1010

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

Idecabtagene vicleucel

Marketed by Bristol-Myers Squibb

Approved in Multiple Myelomacell therapy (autologous CAR-T)
Reliable signal

NCT03651128 · Phase 3 · completed

Randomized, open-label Phase 3 trial (n=386) demonstrating significant improvement in PFS vs standard regimens in relapsed/refractory multiple myeloma (NEJM 2023).

Next expected readout: May 2027 · NCT05393804 (registry estimate)

Reported efficacy

Progression-free survival (PFS): PFS 13.3 vs 4.4 mo (HR 0.49 [95% CI 0.38-0.65], p<0.001); ORR 71% vs 42% (p<0.001) (met)

Result source: NCT03651128

KLN-1010

Developed by Kelonia Therapeutics, Inc.

Phase 1 in Multiple Myelomagene therapy (in vivo lentiviral gene delivery)
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: March 2027 · NCT07075185 (registry estimate)

No aligned efficacy figure on record for this race.

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointIdecabtagene vicleucelKLN-1010
PFS, median8.9bn 137NCT03361748—Not reported
OS, median28.3bn 137NCT03361748—Not reported
ORR74.5%bn 137NCT03361748—Not reported
VGPR or better—Not posted · NCT03651128—Not reported
MRD negativity—Not posted · NCT03651128—Not reported

PFS, median

Idecabtagene vicleucel
8.9bn 137NCT03361748
KLN-1010
—Not reported

OS, median

Idecabtagene vicleucel
28.3bn 137NCT03361748
KLN-1010
—Not reported

ORR

Idecabtagene vicleucel
74.5%bn 137NCT03361748
KLN-1010
—Not reported

VGPR or better

Idecabtagene vicleucel
—Not posted · NCT03651128
KLN-1010
—Not reported

MRD negativity

Idecabtagene vicleucel
—Not posted · NCT03651128
KLN-1010
—Not reported
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

KLN-1010: no structured comparison results are available for Multiple Myeloma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Idecabtagene vicleucel: 3 of 4 rows · KLN-1010: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricIdecabtagene vicleucel
Dropout rate
73.7%a
NCT03361748 · Phase 2
show 1 more result
5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
Discontinued due to AEs
—a
NCT03361748 · Phase 2
show 1 more result
—
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
Serious AEs
78.8%a
NCT03361748 · Phase 2
show 1 more result
22.5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
neutropenia 94.9%
cytokine release syndrome 80.3%
anaemia 75.9%
NCT03361748 · Phase 2
show 1 more result
lymphocyte count decreased 85%
neutrophil count decreased 77.5%
white blood cell decreased 72.5%
NCT05032820 · Phase 2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Idecabtagene vicleucel

ORR 74.5% (n=137)
responder rate · % of participants
No placebo or comparator arm
NCT03361748 · Phase 2
Complete 34.3% (n=137)
responder rate · % of participants
No placebo or comparator arm
NCT03361748 · Phase 2
Time to Response 1 months
time to event · months
No placebo or comparator arm
NCT03361748 · Phase 2
Duration of Response 11.04 months
time to event · months
No placebo or comparator arm
NCT03361748 · Phase 2
PFS 8.9 months
time to event · months
No placebo or comparator arm
NCT03361748 · Phase 2
Time to Progression 10.38 months
time to event · months
No placebo or comparator arm
NCT03361748 · Phase 2
Overall Survival 28.25 months
time to event · months
No placebo or comparator arm
NCT03361748 · Phase 2
VGPR or Better With MRD Negativity 40.9% (n=137)
responder rate · % of participants
No placebo or comparator arm
10^(-5) Sensitivity
NCT03361748 · Phase 2
EORTC QLQ-C30 Physical Functioning -0.4 score @ 0.14wk
absolute change · score
No placebo or comparator arm
NCT03361748 · Phase 2
show 7 more results
2.1 score @ 4.33wk
NCT03361748 · Phase 2
9.8 score @ 13wk
NCT03361748 · Phase 2
13.9 score @ 26wk
NCT03361748 · Phase 2
13.1 score @ 39wk
NCT03361748 · Phase 2
13.3 score @ 52wk
NCT03361748 · Phase 2
12.8 score @ 78wk
NCT03361748 · Phase 2
3.8 score @ 104wk
NCT03361748 · Phase 2
EORTC QLQ-C30 Global Health Status -4.7 score @ 0.14wk
absolute change · score
No placebo or comparator arm
NCT03361748 · Phase 2
show 7 more results
4.3 score @ 4.33wk
NCT03361748 · Phase 2
8.8 score @ 13wk
NCT03361748 · Phase 2
12.5 score @ 26wk
NCT03361748 · Phase 2
15.7 score @ 39wk
NCT03361748 · Phase 2
14.1 score @ 52wk
NCT03361748 · Phase 2
10.6 score @ 78wk
NCT03361748 · Phase 2
7.1 score @ 104wk
NCT03361748 · Phase 2
EORTC QLQ-MY20 Disease Symptoms -0.8 score @ 0.14wk
absolute change · score
No placebo or comparator arm
NCT03361748 · Phase 2
show 7 more results
-10.2 score @ 4.33wk
NCT03361748 · Phase 2
-10.8 score @ 13wk
NCT03361748 · Phase 2
-12.6 score @ 26wk
NCT03361748 · Phase 2
-14.4 score @ 39wk
NCT03361748 · Phase 2
-15.7 score @ 52wk
NCT03361748 · Phase 2
-12 score @ 78wk
NCT03361748 · Phase 2
-13.1 score @ 104wk
NCT03361748 · Phase 2
EORTC QLQ-MY20 Side Effects 2.5 score @ 0.14wk
absolute change · score
No placebo or comparator arm
NCT03361748 · Phase 2
show 7 more results
0 score @ 4.33wk
NCT03361748 · Phase 2
-2.6 score @ 13wk
NCT03361748 · Phase 2
-4.7 score @ 26wk
NCT03361748 · Phase 2
-6.5 score @ 39wk
NCT03361748 · Phase 2
-4 score @ 52wk
NCT03361748 · Phase 2
-3.4 score @ 78wk
NCT03361748 · Phase 2
-3.2 score @ 104wk
NCT03361748 · Phase 2

+ 7 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Idecabtagene vicleucel's landscape · KLN-1010's landscape